Compare CLNE & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLNE | MYGN |
|---|---|---|
| Founded | 2001 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 478.4M | 481.6M |
| IPO Year | 2006 | 1996 |
| Metric | CLNE | MYGN |
|---|---|---|
| Price | $2.15 | $4.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $3.49 | ★ $7.64 |
| AVG Volume (30 Days) | 996.5K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $341,599,000.00 | ★ $771,400,000.00 |
| Revenue This Year | $5.99 | $7.19 |
| Revenue Next Year | $17.00 | $5.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $1.30 | $3.76 |
| 52 Week High | $3.11 | $10.30 |
| Indicator | CLNE | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 37.85 | 43.84 |
| Support Level | $2.11 | $3.93 |
| Resistance Level | $2.26 | $5.63 |
| Average True Range (ATR) | 0.10 | 0.35 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 12.31 | 30.77 |
Clean Energy Fuels Corp is a natural gas marketer and retailer operating in the United States and Canada. The company supplies compressed natural gas and liquefied natural gas for the United States (U.S.) and Canadian transportation markets. The majority of revenue is generated within the U.S. and mostly consists of compressed natural gas. The firm operates by purchasing natural gas from local utilities; compressing, cooling, or liquefying it at company-owned plants; and selling natural gas products through company-owned or customer-owned fueling stations. It also builds, operates, and maintains natural gas fueling stations for customers.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.